Medicare GLP-1 Bridge weight Loss Program

The new Medicare GLP-1 Bridge Program is a temporary federal program that, for the first time, gives certain Medicare beneficiaries access to GLP-1 medications specifically for weight management. It began July 1, 2026 and is currently scheduled to run through December 31, 2027. It operates separately from the beneficiary’s normal Part D benefit.

The basic benefit

An eligible Medicare beneficiary pays $50 for a 28- or 30-day supply of an approved GLP-1 medication. Currently covered are Wegovy injection or tablet, Foundayo tablets, and the Zepbound KwikPen. Zepbound single-dose pens and vials are not included.

The person must have Medicare prescription drug coverage, such as a standalone Part D PDP or qualifying Medicare Advantage plan with Part D. SNPs and certain employer/union Medicare plans can also qualify.

Who qualifies?

CMS uses the person’s BMI when GLP-1 therapy was started, not necessarily today’s BMI. A beneficiary generally qualifies under one of these three pathways:

The medication must be prescribed for reducing excess body weight or maintaining weight reduction, along with an ongoing lifestyle program involving nutrition and physical activity. The physician or other provider must complete a prior authorization.

One of the most important rules

Someone generally cannot use the Bridge Program if Medicare Part D is already covering a GLP-1 for them. In addition, beneficiaries with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or qualifying MASH/fatty liver disease aren’t eligible for the Bridge benefit because GLP-1 treatment for those conditions may already fall under ordinary Part D coverage.

For example, a person taking Mounjaro for type 2 diabetes would normally pursue coverage through their regular Part D plan rather than obtain Zepbound for $50 through the Bridge Program.

The $50 does NOT work like normal Part D spending

This is particularly important when explaining it to Medicare clients. Because the Bridge Program operates outside the regular Part D benefit, the $50 copay:

• does not count toward the 2026 Part D deductible;
• does not count toward the $2,100 Part D out-of-pocket limit;
• cannot be reduced through Extra Help/LIS; and
• cannot be placed into the Medicare Prescription Payment Plan.

How a Medicare client gets the medication

The practical process is generally: the beneficiary speaks with their doctor; the doctor determines whether the BMI/medical criteria are met; a prescription for one of the covered drugs is sent to the pharmacy; and the provider completes the required Bridge prior authorization. Once approved, the authorization can generally remain valid through December 31, 2027, including refills and dose changes, unless the beneficiary switches to a different GLP-1 drug.

Why this is important for Medicare brokers

This program creates a significant distinction that clients may not understand:

GLP-1 prescribed for a Medicare-covered medical indication → regular Part D

versus

GLP-1 prescribed primarily for weight management and meeting the Bridge criteria → $50 Medicare GLP-1 Bridge Program.

And importantly, the beneficiary’s Part D carrier does not have to elect to participate in the Bridge Program; CMS runs the demonstration separately.

If you’d like, I can also prepare a one-page “2026 Medicare GLP-1 Bridge Program” client handout that you could give to your Medicare clients, with the qualification chart and $50 cost explained in very simple language.